EP Patent

EP3769783A1 — Compositions comprising anti-cd38 antibodies and carfilzomib

Assigned to Sanofi SA · Expires 2021-01-27 · 5y expired

What this patent protects

D isclosed herein are compositions and kits which comprise anti-C D 38 antibodies and carfilzomib compounds. A lso disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

USPTO Abstract

D isclosed herein are compositions and kits which comprise anti-C D 38 antibodies and carfilzomib compounds. A lso disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

Drugs covered by this patent

Patent Metadata

Patent number
EP3769783A1
Jurisdiction
EP
Classification
—
Expires
2021-01-27
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.